Zura Bio Limited (ZURA)
| Bid | 1.16 |
| Market Cap | 87.86M |
| Revenue (ttm) | 1.82K |
| Net Income (ttm) | -43.47M |
| EPS (ttm) | -0.6 |
| PE Ratio (ttm) | -2.14 |
| Forward PE | -2.2 |
| Analyst | Buy |
| Ask | 1.37 |
| Volume | 354,420 |
| Avg. Volume (20D) | 351,211 |
| Open | 1.28 |
| Previous Close | 1.26 |
| Day's Range | 1.17 - 1.35 |
| 52-Week Range | 1.07 - 6.35 |
| Beta | 0.06 |
About ZURA
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California....
Analyst Forecast
According to 7 analyst ratings, the average rating for ZURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 1067.32% from the latest price.
Stock Forecasts
1 month ago · businesswire.com
Zura Bio to Present at the Leerink Partners Global Healthcare ConferenceHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoim...
